With respect to increased survival, treatment with a single dose of memory B or CD4+ T cells was as effective as a three-day treatment with sulbactam at pharmacodynamically optimized doses in the pneumonia murine model for both strains. Here, CD4 is linked to susceptibility to pneumonia measurement.